## **Core Concept**
Familial hyperkalemic periodic paralysis (FHPP) is a rare genetic disorder characterized by episodes of muscle weakness and hyperkalemia. It is caused by mutations in the **SCN4A** gene, which encodes for a subunit of the voltage-gated sodium channel in skeletal muscle. This condition leads to an abnormality in sodium channel function, affecting muscle excitability.

## **Why the Correct Answer is Right**
The drug of choice for managing familial hyperkalemic periodic paralysis is **acetazolamide**, a carbonic anhydrase inhibitor. Acetazolamide works by reducing the severity and frequency of attacks through mechanisms that are not entirely clear but may involve effects on potassium handling and muscle membrane stabilization. It is often used as a prophylactic measure to decrease the frequency of episodes.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Not specified, but assuming it's a wrong option, without knowing the specific drug it's hard to comment. However, generally, drugs that are not known to affect sodium channels or potassium handling in the context of FHPP would be incorrect.
- **Option B:** Similarly, without specifics, if it's not acetazolamide or another known treatment like **spironolactone** or **thiazide diuretics** which have some role in managing potassium levels, it would be incorrect.
- **Option C:** This option is also unspecified, but if it doesn't relate to known treatments for FHPP, it's incorrect.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **acetazolamide** is not only used for FHPP but also for other conditions like glaucoma, epilepsy, and altitude sickness. In the context of FHPP, it's crucial to monitor potassium levels and renal function. Another clinical pearl is that **spironolactone**, a potassium-sparing diuretic, might seem counterintuitive but can sometimes be used in conjunction or as an alternative in managing some aspects of the condition.

## **Correct Answer:** . **acetazolamide**